flurbiprofen has been researched along with clonidine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Camras, CB; Lustgarten, JS; Podos, SM; Siegel, MJ | 1 |
| Arkin, LM; Cummings, HL; Robin, AL; Sulewski, ME | 1 |
| Brubaker, RF; Koskela, T; McCannel, C | 1 |
| Bhuyan, DK; Bhuyan, KC; Camras, CB; Lee, KW; Podos, SM; Wang, RF | 1 |
| Maekawa, N; Mikawa, K; Nishina, K; Obara, H; Shiga, M; Takao, Y | 1 |
1 review(s) available for flurbiprofen and clonidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for flurbiprofen and clonidine
| Article | Year |
|---|---|
Effect of flurbiprofen on the reduction of intraocular pressure after administration of 1% apraclonidine in patients with glaucoma.
Topics: Clonidine; Flurbiprofen; Glaucoma; Humans; Intraocular Pressure; Osmolar Concentration | 1992 |
Effects of topical flurbiprofen on the intraocular pressure lowering effects of apraclonidine and timolol.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Clonidine; Double-Blind Method; Evaluation Studies as Topic; Female; Flurbiprofen; Humans; Intraocular Pressure; Male; Middle Aged; Premedication; Prospective Studies; Timolol | 1991 |
Topical flurbiprofen pretreatment does not block apraclonidine's effect on aqueous flow in humans.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Aqueous Humor; Clonidine; Double-Blind Method; Female; Fluorescein; Fluoresceins; Fluorophotometry; Flurbiprofen; Humans; Male; Premedication | 1991 |
Diclofenac and flurbiprofen with or without clonidine for postoperative analgesia in children undergoing elective ophthalmological surgery.
Topics: Administration, Oral; Administration, Rectal; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Clonidine; Diclofenac; Drug Therapy, Combination; Elective Surgical Procedures; Flurbiprofen; Humans; Injections, Intravenous; Ophthalmologic Surgical Procedures; Pain Measurement; Pain, Postoperative | 2000 |
14 other study(ies) available for flurbiprofen and clonidine
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
The role of prostaglandins in the para-aminoclonidine-induced reduction of intraocular pressure.
Topics: Administration, Topical; Animals; Aqueous Humor; Clonidine; Dinoprost; Dinoprostone; Disease Models, Animal; Female; Flurbiprofen; Glaucoma; Intraocular Pressure; Laser Therapy; Macaca fascicularis; Pupil | 1989 |